View ValuationPacific Edge 향후 성장Future 기준 점검 2/6Pacific Edge (는) 각각 연간 51% 및 30.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 59% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -59.1% 로 예상됩니다.핵심 정보51.0%이익 성장률58.99%EPS 성장률Biotechs 이익 성장25.2%매출 성장률30.2%향후 자기자본이익률-59.14%애널리스트 커버리지Low마지막 업데이트17 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 15Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 149,411,765 Price\Range: NZD 0.17 Transaction Features: Subsequent Direct Listing공시 • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026공시 • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025공시 • Jun 16Pacific Edge Limited, Annual General Meeting, Aug 06, 2025Pacific Edge Limited, Annual General Meeting, Aug 06, 2025. Location: auckland New Zealand공시 • Jun 03Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: NZD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: NZD 0.1 Transaction Features: Subsequent Direct Listing공시 • May 31Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million.Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: NZD 0.1공시 • May 30Pacific Edge Limited has filed a Follow-on Equity Offering.Pacific Edge Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listing공시 • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025공시 • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024공시 • May 07Pacific Edge Limited, Annual General Meeting, Sep 24, 2024Pacific Edge Limited, Annual General Meeting, Sep 24, 2024.공시 • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024공시 • Mar 14Pacific Edge Limited Announces Board ChangesPacific Edge Limited announced the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. Mr. Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his governance commitments, and has indicated his intention to retire from the Board following the appointment of a successor and a structured handover at the end of this year. Meanwhile, with his family having made new commitments offshore, Mr. Green has notified the Board he does not intend to seek re-election at the company's next Annual Shareholders Meeting in September. Mr. Green joined the Pacific Edge Board in May 2021. The Board's Nomination Committee has commenced a process to appoint a new Chair and consider the recruitment of new Independent Directors.공시 • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023공시 • Jun 09Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023Pacific Edge announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. This development follows the finalization of a Local Coverage Determination (LCD) (L39365) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania. The finalized LCD, which includes Cxbladder and tests provided by other companies, specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as `not considered medically reasonable and necessary', the threshold required for coverage under the US Social Security Act. A number of other companies are also affected by the LCD. Over the coming days Pacific Edge will seek to explore all available legal options (including a potential appeal) with US-based lawyers, the key opinion leaders among customers, partners at The Coalition for 21st Century Medicine, and other impacted companies. Pacific Edge is currently unable to fully determine the impact of the new LCD on test volumes in the US market for the 2024 financial year. For the immediate future, the company will continue to promote Cxbladder and process all tests ordered by US clinicians whilst it further considers its strategy and future options. The company believes that in the short term it is prudent to continue to support Cxbladder as it determines the best path forward, but the approach will be accompanied by cost containment initiatives including, but not limited to an immediate hiring freeze and a halt on discretionary spending and new capital expenditure. In light of this new LCD, management and the Board at Pacific Edge are reviewing the scenario planning commenced last year to determine a strategic path forward that potentially includes: a) legal challenges or appeals, b) seeking to regain coverage through Novitas, c) seeking to be awarded coverage through an alternative MAC, d) alternative billing practices that would increase patient responsibility and e) remaining open to other strategic alternatives. Which of these the company adopts, will be determined by considering a number of factors including the potential impact on revenue, expenditure and cash reserves, the time and resources required to regain coverage, shareholder value implications, and the expected likelihood of success.New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$53.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$3.9m net loss in 3 years). Market cap is less than US$100m (US$53.3m market cap).이익 및 매출 성장 예측OTCPK:PFGT.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (NZD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/202831-4N/A213/31/202721-25N/A-2713/31/202611-36N/A3419/30/202518-35-32-31N/A6/30/202520-32-29-28N/A3/31/202523-30-26-25N/A12/31/202423-29-25-24N/A9/30/202423-29-24-23N/A6/30/202424-29-26-24N/A3/31/202425-30-27-26N/A12/31/202325-31-28-26N/A9/30/202326-32-29-27N/A6/30/202323-29-29-26N/A3/31/202321-27-28-26N/A12/31/202219-24-27-24N/A9/30/202216-21-25-23N/A6/30/202215-21-22-20N/A3/31/202213-20-19-18N/A12/31/202112-18-17-16N/A9/30/202112-16-15-15N/A6/30/202110-15-15-14N/A3/31/20219-14-14-14N/A12/31/20207-15-15-15N/A9/30/20206-17-16-16N/A6/30/20205-18-16-16N/A3/31/20205-19-16-15N/A12/31/20195-19-16-16N/A9/30/20195-19-16-16N/A6/30/20195-18N/A-17N/A3/31/20195-18N/A-18N/A12/31/20185-18N/A-17N/A9/30/20185-18N/A-17N/A6/30/20185-19N/A-17N/A3/31/20185-20N/A-18N/A12/31/20174-20N/A-19N/A9/30/20173-21N/A-19N/A6/30/20174-22N/A-18N/A3/31/20174-23N/A-18N/A12/31/20166-21N/A-18N/A9/30/20168-20N/A-17N/A6/30/20167-18N/A-17N/A3/31/20166-16N/A-17N/A12/31/20155-15N/A-16N/A9/30/20154-15N/A-16N/A6/30/20154-14N/A-14N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: PFGT.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: PFGT.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: PFGT.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: PFGT.F 의 수익(연간 30.2%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: PFGT.F 의 수익(연간 30.2%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: PFGT.F는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 14:38종가2026/05/15 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pacific Edge Limited는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullBrookline Capital MarketsMaxim JacobsEdison Investment ResearchMatt MontgomerieForsyth Barr Group Ltd.4명의 분석가 더 보기
공시 • May 15Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 149,411,765 Price\Range: NZD 0.17 Transaction Features: Subsequent Direct Listing
공시 • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026
공시 • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025
공시 • Jun 16Pacific Edge Limited, Annual General Meeting, Aug 06, 2025Pacific Edge Limited, Annual General Meeting, Aug 06, 2025. Location: auckland New Zealand
공시 • Jun 03Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: NZD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: NZD 0.1 Transaction Features: Subsequent Direct Listing
공시 • May 31Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million.Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: NZD 0.1
공시 • May 30Pacific Edge Limited has filed a Follow-on Equity Offering.Pacific Edge Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listing
공시 • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025
공시 • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024
공시 • May 07Pacific Edge Limited, Annual General Meeting, Sep 24, 2024Pacific Edge Limited, Annual General Meeting, Sep 24, 2024.
공시 • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024
공시 • Mar 14Pacific Edge Limited Announces Board ChangesPacific Edge Limited announced the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. Mr. Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his governance commitments, and has indicated his intention to retire from the Board following the appointment of a successor and a structured handover at the end of this year. Meanwhile, with his family having made new commitments offshore, Mr. Green has notified the Board he does not intend to seek re-election at the company's next Annual Shareholders Meeting in September. Mr. Green joined the Pacific Edge Board in May 2021. The Board's Nomination Committee has commenced a process to appoint a new Chair and consider the recruitment of new Independent Directors.
공시 • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023
공시 • Jun 09Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023Pacific Edge announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. This development follows the finalization of a Local Coverage Determination (LCD) (L39365) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania. The finalized LCD, which includes Cxbladder and tests provided by other companies, specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as `not considered medically reasonable and necessary', the threshold required for coverage under the US Social Security Act. A number of other companies are also affected by the LCD. Over the coming days Pacific Edge will seek to explore all available legal options (including a potential appeal) with US-based lawyers, the key opinion leaders among customers, partners at The Coalition for 21st Century Medicine, and other impacted companies. Pacific Edge is currently unable to fully determine the impact of the new LCD on test volumes in the US market for the 2024 financial year. For the immediate future, the company will continue to promote Cxbladder and process all tests ordered by US clinicians whilst it further considers its strategy and future options. The company believes that in the short term it is prudent to continue to support Cxbladder as it determines the best path forward, but the approach will be accompanied by cost containment initiatives including, but not limited to an immediate hiring freeze and a halt on discretionary spending and new capital expenditure. In light of this new LCD, management and the Board at Pacific Edge are reviewing the scenario planning commenced last year to determine a strategic path forward that potentially includes: a) legal challenges or appeals, b) seeking to regain coverage through Novitas, c) seeking to be awarded coverage through an alternative MAC, d) alternative billing practices that would increase patient responsibility and e) remaining open to other strategic alternatives. Which of these the company adopts, will be determined by considering a number of factors including the potential impact on revenue, expenditure and cash reserves, the time and resources required to regain coverage, shareholder value implications, and the expected likelihood of success.
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$53.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$3.9m net loss in 3 years). Market cap is less than US$100m (US$53.3m market cap).